Human Cytomegalovirus Infection in Haematopoietic Stem Cell Transplant Recipients and CAR T Cell Recipients – PART 1: Risk Factors, Clinical Impact and Immune Response
Open Access
- 14 April 2026
- journal article
- review article
- Published by Wiley in Reviews in Medical Virology
- Vol. 36 (3) , e70142
Abstract
Human cytomegalovirus (HCMV) is one of the most important opportunistic pathogens in immunocompromised individuals, including allogeneic haematopoietic stem cell transplant (allo‐HSCT) recipients. In allo‐HSCT, HCMV seropositivity of the recipient and donor is associated with inferior survival outcomes, and post‐transplant HCMV reactivation is a frequent complication, necessitating close viral monitoring and pre‐emptive and prophylactic antiviral therapies. We present a review in two parts that focuses on the risk factors, immunological responses and treatment strategies for HCMV infection in allo‐HSCT recipients, and also explores current evidence surrounding HCMV reactivation in recipients of chimeric antigen receptor T cell (CAR T) therapies. In the current article (Part 1), the impact of HCMV infection in allo‐HSCT and CAR T cell recipients is investigated. HCMV reactivation in allo‐HSCT recipients is associated with increased mortality, graft‐versus‐host disease (GvHD) and other microbial infections. Prominent alterations in T cell and natural killer (NK) cell recovery represent distinct immune reconstitution features associated with HCMV reactivation. Immunological biomarkers to predict HCMV complications have been proposed and their adoption in future immune monitoring strategies may allow individualised risk assessment to guide antiviral treatment decisions. The clinical significance of HCMV reactivation after CAR T cell infusion is yet to be fully determined. Continued viral surveillance and investigation of viral dynamics with correlative studies of immune function are needed in this patient population. Current and emerging strategies for treatment and prevention of HCMV complications in allo‐HSCT, including use of letermovir prophylaxis and adoptive HCMV‐specific T cell therapies, are explored in the following article (Part 2).Keywords
This publication has 199 references indexed in Scilit:
- Peripheral blood CD14(+) cells from healthy subjects carry a circular conformation of latent cytomegalovirus genome.1999
- Kinetics of the Antibody Response against Human Cytomegalovirus–Specific Proteins in Allogeneic Bone Marrow Transplant RecipientsThe Journal of Infectious Diseases, 1998
- Human Cytomegalovirus Persistently Infects Aortic Endothelial CellsJournal of Virology, 1998
- Cytomegalovirus remains latent in a common precursor of dendritic and myeloid cellsProceedings of the National Academy of Sciences, 1998
- Reactivation of Latent Human Cytomegalovirus by Allogeneic Stimulation of Blood Cells from Healthy DonorsCell, 1997
- Detection of endogenous human cytomegalovirus in CD34+ bone marrow progenitorsJournal of General Virology, 1996
- Human cytomegalovirus inhibits antigen presentation by a sequential multistep process.Proceedings of the National Academy of Sciences, 1996
- Cytotoxic T-lymphocyte response to cytomegalovirus after human allogeneic bone marrow transplantation: pattern of recovery and correlation with cytomegalovirus infection and disease.1991
- Monocytes are a major site of persistence of human cytomegalovirus in peripheral blood mononuclear cellsJournal of General Virology, 1991
- Use of leukocyte-depleted platelets and cytomegalovirus-seronegative red blood cells for prevention of primary cytomegalovirus infection after marrow transplant.1991